Gland Pharma Limited has informed the Exchange about Transcript
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma reported consolidated Q1FY26 revenue of INR 15,056 million, up 7% year-on-year, with consolidated EBITDA jumping 39% to INR 3,678 million and EBITDA margin expanding from 19% to 24%. Net profit grew 50% to INR 2,155 million, with PAT margin rising from 10% to 14%, driven by gross margin improvement to 65% from 60%. The US business contributed INR 7,443 million (49% of revenue) with 9 new product launches, while other regulated markets grew 34% YoY. Subsidiary Cenexi turned EBITDA breakeven (EUR 0.9 million on EUR 48 million revenue) after several quarters of losses, marking a key turnaround milestone. The company is expanding pen and cartridge capacity from 40 million to 140 million units to support its GLP-1 strategy, with a new ESOP 2025 scheme launched in May 2025.
The strong margin expansion and Cenexi's return to breakeven are positive for shareholders, reinforcing management's confidence in FY26 delivery. Investors should note the upcoming capacity build-out (capex of INR 786 million in Q1) and the company's continued push into complex injectables, RTU bags, and GLP-1 products, which could drive medium-term growth but may also pressure near-term margins during the Q2FY26 summer shutdown at Cenexi.